The PRKAB1 antibody is a key tool for studying the β1 regulatory subunit of AMP-activated protein kinase (AMPK), a critical energy sensor involved in maintaining cellular metabolic homeostasis. AMPK, a heterotrimeric enzyme composed of α, β, and γ subunits, is activated under low-energy conditions (e.g., ATP depletion) and regulates glucose uptake, lipid metabolism, and mitochondrial biogenesis. The PRKAB1 (β1) subunit plays a structural role in stabilizing the AMPK complex and modulates its activity through interactions with other subunits. Research using PRKAB1 antibodies has elucidated its role in metabolic disorders (e.g., diabetes, obesity), cancer (where AMPK signaling often dysregulates tumor growth), and cardiovascular diseases. These antibodies are widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and post-translational modifications in tissues or cultured cells. Many commercially available PRKAB1 antibodies are raised in hosts like rabbits or mice, with validation data confirming specificity via knockout controls or siRNA knockdown. Recent studies also explore PRKAB1's involvement in autophagy, aging, and response to therapies targeting metabolic pathways. However, researchers must verify cross-reactivity with homologous subunits (e.g., PRKAB2/β2) and optimize protocols for different sample types due to potential variability in detection.